Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|June 30, 2009
Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part one: lead identificationIan P Holmes, Fabrizio Micheli, Simon Gaines, et al.Journal of Neuroscience Methods|October 24, 2002
High-performance liquid chromatography/tandem mass spectrometry assay for the rapid high sensitivity measurement of basal acetylcholine from microdialysatesMark E P Hows, Andrew J Organ, Sarah Murray, et al.Bioorganic & Medicinal Chemistry Letters|January 21, 2016
Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonistsFabrizio Micheli, Susanna Cremonesi, Teresa Semeraro, et al.Drug and Alcohol Dependence|November 18, 2021
Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VASBrent Boyett, Katharina Wiest, Lori D McLeod, et al.Journal of Addiction Medicine|March 19, 2020
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational StudyWalter Ling, Vijay R Nadipelli, Arnie P Aldridge, et al.Lancet (London, England)|February 23, 2019
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialBarbara R Haight, Susan M Learned, Celine M Laffont, et al.Journal of Clinical Psychopharmacology|April 14, 2020
Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy AnalysisAnne C Andorn, Barbara R Haight, Sunita Shinde, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 13, 2012
Occupancy of brain dopamine D3 receptors and drug craving: a translational approachManolo Mugnaini, Laura Iavarone, Palmina Cavallini, et al.Bioorganic & Medicinal Chemistry Letters|June 26, 2009
Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimizationFabrizio Micheli, Ian Holmes, Luca Arista, et al.Regulatory Toxicology and Pharmacology : RTP|December 19, 2009
Hypotheses and fundamental study design characteristics for evaluating potential reduced-risk tobacco products. Part I: HeuristicLenn Murrelle, Christopher R E Coggins, Chris Gennings, et al.Pageof 7